CrushSCI.com
232平均天数
232中位天数
232最短天数
232最长天数
1212025发文量

Paper Review Records

全部论文审稿周期

1 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

232 天

Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial

作者
Ying Liu; Xiangjiao Meng; Yan Yu; Jianhua Chen; Runxiang Yang; Laiyu Liu; Yanqiu Zhao; Ruifen Tian; Dianming Li; Ruiling Ning; Qingshan Li; Guowu Wu; Li Wang; Xianghui Duan; Xuejie Guo; Yan Hu; Weili Liu; Haifeng Liu展开收起
作者单位
1. Department of Oncology , Jilin Provincial Cancer Hospital , Changchun, Jilin, P. R. China .; 2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute , Shandong First Medical University and Shandong Academy of Medical Sciences , Jinan, Shandong, P. R. China .; 3. Department of Thoracic Medical Oncology , The Affiliated Cancer Hospital of Harbin Medical University , Harbin, Heilongjiang, P. R. China .; 4. Department of Thoracic Medical Oncology , Hunan Provincial Cancer Hospital , Changsha, Hunan, P. R. China .; 5. Department of Medical Oncology , Yunnan Provincial Cancer Hospital , Kunming, Yunnan, P. R. China .; 6. Department of Respiratory and Critical Care Medicine , Nanfang Hospital Affiliated to Southern Medical University , Guangzhou, Guangdong, P. R. China .; 7. Department of Thoracic Medical Oncology , The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital , Zhengzhou, Henan, P. R. China .; 8. Department of Respiratory Oncology , Shanxi Provincial Cancer Hospital , Taiyuan, Shanxi, P. R. China .; 9. Department of Respiratory and Critical Care Medicine , The First Affiliated Hospital of Bengbu Medical College , Bengbu, Anhui, P. R. China .; 10. Department of Respiratory Medical Oncology , The Affiliated Cancer Hospital of Guangxi Medical University , Nanning, Guangxi Zhuang Autonomous Region, P. R. China .; 11. Department of Oncology , The Affiliated Hospital of Chengde Medical University , Chengde, Hebei, P. R. China .; 12. Department of Medical Oncology , Meizhou People’s Hospital , Meizhou, Guangdong, P. R. China .; 13. Department of Clinical Science , Xuanzhu Biopharmaceutical Co. Ltd. , Beijing, P. R. China .展开收起
PDF源文件 DOI 网页

FAQ

Cancer Communications审稿要多久?

截至2026-11-19,CrushSCI 只收录了 Cancer Communications 的 1 篇完整审稿记录:Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial,2026-03-02 收稿,2026-10-20 录用,审稿 232 天。只有一篇样本,结果仅供参考。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。